FDA Places Divi’s Facility on Import Alert Post author:Sam Post published:March 27, 2017 Post category:Drug Industry Daily The FDA placed a Divi’s Laboratories API manufacturing facility in India on an import alert. Source: Drug Industry Daily You Might Also Like Gottlieb Says Contracting System Is ‘Rigged’ Against Biosimilars March 7, 2018 Warning Letters Trend Toward Component Testing, Contractor Oversight in 2022 April 18, 2023 Dr. Reddy’s Hit With 483 for Supplier Quality Agreements, CAPA Issues March 30, 2018